Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Destiny Pharma Medical Equipment & Supplies In Usa
5 equipment items found
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
There are two XF-73 dermal programmes in development. One is being run by our China partner and shareholder – China Medical Systems Holdings Limited (CMS) – focused on superficial skin infections and the other is an in-house programme looking at the use of XF-73 for the prevention and treatment of serious infections associated with burns and open wounds such as diabetic foot ulcers ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action. Destiny Pharma’s XF platform has advantages over traditional antibiotics. ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
Background to the NTCD-M3 Clostridioides difficile Programme. NTCD-M3 was developed by GI infection physician, Professor Dale Gerding, who is a world-leading specialist in C. difficile, with more than 400 peer-reviewed journal publications, book chapters and review articles in the area. NTCD-M3 has successfully completed Phase 1 and Phase 2b trials with NTCD-M3. The Phase 1 study demonstrated a ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
Destiny Pharma is working in collaboration with SporeGen Limited, a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19. SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment. ...
Manufactured by:Destiny Pharma plc based inBrighton, UNITED KINGDOM
A Phase 2b clinical study, which was a multi-centre, randomized, placebo-controlled study of XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) completed recruitment at the end of 2020 and top-line results were reported in Q1 2021, as ...